Valery Shulman, MD
Geriatric Medicine · West Hollywood, CANPI 1871594648
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,158 and has fallen 65.5% since, to $399 in 2025.
Across 99 payments — averaging $34.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$688
- Johnson & Johnson$618
- AstraZeneca$338
- Bayer$293
- Novartis$259
- Biohaven Pharmaceutical Holding Company Ltd.$256
- plus $941 from 15 others
What the payments were for
- Food & beverage$3,394100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 27 | $688 |
| Johnson & Johnson | 5 | $618 |
| AstraZeneca | 11 | $338 |
| Bayer | 4 | $293 |
| Novartis | 13 | $259 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $256 |
| AbbVie | 9 | $206 |
| Avanir Pharmaceuticals, Inc. | 3 | $163 |
| Kowa Pharmaceuticals America, Inc. | 7 | $133 |
| Bristol Myers Squibb | 1 | $125 |
| Lilly USA, LLC | 3 | $59 |
| Novo Nordisk | 2 | $37 |
| Shield Therapeutics Inc | 1 | $34 |
| UCB, Inc. | 1 | $33 |
| Merck | 2 | $31 |
| Gilead | 1 | $23 |
| Eisai Inc. | 1 | $23 |
| Pfizer | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Astellas Pharma US Inc | 1 | $16 |
| Redhill Biopharma Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,394 in reported general payments places this provider in the 85th percentile of 494 geriatric medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 117 | $111,381 |
| OtezlaApremilast | 16 | $67,800 |
| Lactulose | 90 | $63,563 |
| Diclofenac Sodium | 191 | $63,488 |
| CreonLipase/Protease/Amylase | 82 | $55,364 |
| LinzessLinaclotide | 92 | $50,551 |
| EliquisApixaban | 75 | $43,820 |
| Dexlansoprazole DrDexlansoprazole | 224 | $41,639 |
| JanumetSitagliptin Phos/Metformin Hcl | 63 | $39,205 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 29 | $31,123 |
| MounjaroTirzepatide | 26 | $30,696 |
| Diflorasone Diacetate | 53 | $30,164 |
| DapagliflozinDapagliflozin Propanediol | 55 | $28,025 |
| FarxigaDapagliflozin Propanediol | 46 | $25,510 |
| NeuproRotigotine | 28 | $22,602 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $37 | $125,976133 claims |
| AbbVieCreon, Linzess, Restasis | $206 | $116,075190 claims |
| AmgenOtezla | $688 | $67,80016 claims |
| MerckJanumet, Januvia | $31 | $60,78097 claims |
| PfizerEliquis | $21 | $43,82075 claims |
| Lilly USA, LLCMounjaro | $59 | $30,69626 claims |
| AstraZenecaFarxiga | $338 | $25,51046 claims |
| UCB, Inc.Neupro | $33 | $22,60228 claims |
| Johnson & JohnsonXarelto | $618 | $22,12821 claims |
| BayerKerendia | $293 | $7,77912 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $7,34617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 494 geriatric medicine providers in California.
Other geriatric medicine in West Hollywood
- Robert FeldmanLaguna Hills$1.2M
- Oscar ChienSan Gabriel$208K
- Anders NybergSan Diego$160K
- Paul AisenSan Diego$70K
- Wayne ChenLos Angeles$40K
- Vincent HoLancaster$32K
- Kathryn SewellSan Francisco$26K
- Stephen HenryPasadena$25K
- Chaewon SongGarden Grove$21K
- Douglas ZhangSan Leandro$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.